The study aims to evaluate how detectable ctHPVDNA (circulating tumor HPV DNA) is in patients with HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) after surgery but before starting additional therapy, and to assess if this detectability indicates a higher risk of cancer recurrence.
A total of 204 samples were analyzed from patients, including 45 pre-surgery and 159 post-surgery, with significant findings that 94% had ctHPVDNA detectable before surgery, while only 41% did post-surgery.
Results showed that patients with detectable ctHPVDNA after surgery had an 83% survival rate without recurrence after 18 months, compared to a 100% rate for those